Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
J Clin Apher ; 39(3): e22116, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38647036

ABSTRACT

Gemtuzumab ozogamicin (GO) is a CD33 monoclonal antibody-drug conjugate currently in use to treat myeloid malignancies. A unique adverse effect of this medication is destruction of CD33 positive macrophages resulting in reduced clearance of free hemoglobin leading to grossly red plasma. This build-up of free hemoglobin can potentially lead to end organ damage and prevent performance of clinically necessary laboratory evaluation. We present a case of a pediatric patient who developed this adverse effect and was successfully treated with therapeutic plasma exchange (TPE). We also present results from a systematic review of the medical literature and share data from a query of the United States Food and Drug Administration (FDA) Adverse Event Reporting system for GO-related hemoglobin scavenging impairment. Among reported cases, patients undergoing TPE and those receiving steroids had improved outcomes. Practitioners should be aware of this rare drug side-effect and the potential utility of TPE for these patients.


Subject(s)
Gemtuzumab , Hemoglobins , Plasma Exchange , Humans , Gemtuzumab/therapeutic use , Plasma Exchange/methods , Hemoglobins/analysis , Sialic Acid Binding Ig-like Lectin 3 , Male , Aminoglycosides/adverse effects , Female , Antibodies, Monoclonal, Humanized/therapeutic use
2.
J Pediatr Hematol Oncol ; 46(3): e241-e243, 2024 Apr 01.
Article in English | MEDLINE | ID: mdl-38447104

ABSTRACT

Patients undergoing therapy for T cell acute lymphoblastic leukemia are at risk of infections during their treatment course. Cat scratch disease caused by Bartonella hensalae can masquerade as leukemic relapse and cause systemic infection. Obtaining a thorough exposure history may aid clinicians in making the diagnosis.


Subject(s)
Bartonella henselae , Cat-Scratch Disease , Lymphadenopathy , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma , Humans , Cat-Scratch Disease/complications , Cat-Scratch Disease/diagnosis , Cat-Scratch Disease/drug therapy , Lymphadenopathy/etiology , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/complications , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , T-Lymphocytes
3.
Cell Rep Med ; 4(6): 101091, 2023 06 20.
Article in English | MEDLINE | ID: mdl-37343516

ABSTRACT

GD2-targeting immunotherapies have improved survival in children with neuroblastoma, yet on-target, off-tumor toxicities can occur and a subset of patients cease to respond. The majority of neuroblastoma patients who receive immunotherapy have been previously treated with cytotoxic chemotherapy, making it paramount to identify neuroblastoma-specific antigens that remain stable throughout standard treatment. Cell surface glycoproteomics performed on human-derived neuroblastoma tumors in mice following chemotherapy treatment identified protein tyrosine kinase 7 (PTK7) to be abundantly expressed. Furthermore, PTK7 shows minimal expression on pediatric-specific normal tissues. We developed an anti-PTK7 chimeric antigen receptor (CAR) and find PTK7 CAR T cells specifically target and kill PTK7-expressing neuroblastoma in vitro. In vivo, human/murine binding PTK7 CAR T cells regress aggressive neuroblastoma metastatic mouse models and prolong survival with no toxicity. Together, these data demonstrate preclinical efficacy and tolerability for targeting PTK7 and support ongoing investigations to optimize PTK7-targeting CAR T cells for neuroblastoma.


Subject(s)
Neuroblastoma , Receptors, Chimeric Antigen , Humans , Child , Animals , Mice , Neuroblastoma/therapy , Neuroblastoma/pathology , Immunotherapy , Receptors, Chimeric Antigen/genetics , Protein-Tyrosine Kinases
4.
Pediatr Blood Cancer ; 70(8): e30405, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37158620

ABSTRACT

BACKGROUND: 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) can inhibit tumor proliferation, angiogenesis, and restore apoptosis in preclinical pediatric solid tumor models. We conducted a phase 1 trial to determine the maximum tolerated dose (MTD) of simvastatin with topotecan and cyclophosphamide in children with relapsed/refractory solid and central nervous system (CNS) tumors. METHODS: Simvastatin was administered orally twice daily on days 1-21, with topotecan and cyclophosphamide intravenously on days 1-5 of a 21-day cycle. Four simvastatin dose levels (DLs) were planned, 140 (DL1), 180 (DL2), 225 (DL3), 290 (DL4) mg/m2 /dose, with a de-escalation DL of 100 mg/m2 /dose (DL0) if needed. Pharmacokinetic and pharmacodynamic analyses were performed during cycle 1. RESULTS: The median age of 14 eligible patients was 11.5 years (range: 1-23). The most common diagnoses were neuroblastoma (N = 4) and Ewing sarcoma (N = 3). Eleven dose-limiting toxicity (DLT)-evaluable patients received a median of four cycles (range: 1-6). There were three cycle 1 DLTs: one each grade 3 diarrhea and grade 4 creatine phosphokinase (CPK) elevations at DL1, and one grade 4 CPK elevation at DL0. All patients experienced at least one grade 3/4 hematologic toxicity. Best overall response was partial response in one patient with Ewing sarcoma (DL0) and stable disease for four or more cycles in four patients. Simvastatin exposure increased with higher doses and may have correlated with toxicity. Plasma interleukin 6 (IL-6) concentrations (N = 6) showed sustained IL-6 reductions with decrease to normal values by day 21 in all patients, indicating potential on-target effects. CONCLUSIONS: The MTD of simvastatin with topotecan and cyclophosphamide was determined to be 100 mg/m2 /dose.


Subject(s)
Central Nervous System Neoplasms , Neoplasms , Neuroectodermal Tumors, Primitive, Peripheral , Sarcoma, Ewing , Humans , Child , Infant , Child, Preschool , Adolescent , Young Adult , Adult , Topotecan , Simvastatin/adverse effects , Interleukin-6 , Cyclophosphamide , Neoplasms/drug therapy , Central Nervous System Neoplasms/drug therapy , Central Nervous System Neoplasms/etiology , Maximum Tolerated Dose , Antineoplastic Combined Chemotherapy Protocols/adverse effects
5.
Pediatr Blood Cancer ; 70(6): e30283, 2023 06.
Article in English | MEDLINE | ID: mdl-36896566

ABSTRACT

BACKGROUND: Progressive transformation of germinal centers (PTGC) is a rare diagnosis characterized by asymptomatic lymph node enlargement. It has previously been associated with lymphoma, autoimmune conditions, and lymphoproliferative diseases in small pediatric case series. PROCEDURES: We conducted a single-center retrospective review of pediatric cases of PTGC diagnosed at our institution by hematopathologists from 2000 to 2020. RESULTS: We identified 57 primary cases and three recurrent cases of PTGC. Laboratory and imaging evaluations were obtained inconsistently. Nine patients (16%) saw a pediatric hematology/oncology (PHO) specialist prior to diagnosis, and 21 (37%) had follow-up with PHO after diagnosis. CONCLUSIONS: Patients with PTGC had similar age and involved lymph node sites to those from previous case series. Fewer patients underwent recurrent lymph node biopsy than previously described. PTGC has been linked to certain types of lymphoma, although never definitively associated with lymphoma. Follow-up with a PHO provider is indicated to ensure that close surveillance is performed.


Subject(s)
Germinal Center , Lymphoma , Humans , Child , Retrospective Studies , Germinal Center/pathology , Lymphoma/pathology , Cell Transformation, Neoplastic/pathology , Lymph Nodes/pathology
6.
J Clin Oncol ; 41(3): 508-516, 2023 01 20.
Article in English | MEDLINE | ID: mdl-36206505

ABSTRACT

PURPOSE: Although chemoimmunotherapy is widely used for treatment of children with relapsed high-risk neuroblastoma (HRNB), little is known about timing, duration, and evolution of response after irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) therapy. PATIENTS AND METHODS: Patients eligible for this retrospective study were age < 30 years at diagnosis of HRNB and received ≥ 1 cycle of I/T/DIN/GM-CSF for relapsed or progressive disease. Patients with primary refractory disease who progressed through induction were excluded. Responses were evaluated using the International Neuroblastoma Response Criteria. RESULTS: One hundred forty-six patients were included. Tumors were MYCN-amplified in 50 of 134 (37%). Seventy-one patients (49%) had an objective response to I/T/DIN/GM-CSF (objective response; 29% complete response, 14% partial response [PR], 5% minor response [MR], 21% stable disease [SD], and 30% progressive disease). Of patients with SD or better at first post-I/T/DIN/GM-CSF disease evaluation, 22% had an improved response per International Neuroblastoma Response Criteria on subsequent evaluation (13% of patients with initial SD, 33% with MR, and 41% with PR). Patients received a median of 4.5 (range, 1-31) cycles. The median progression-free survival (PFS) was 13.1 months, and the 1-year PFS and 2-year PFS were 50% and 28%, respectively. The median duration of response was 15.9 months; the median PFS off all anticancer therapy was 10.4 months after discontinuation of I/T/DIN/GM-CSF. CONCLUSION: Approximately half of patients receiving I/T/DIN/GM-CSF for relapsed HRNB had objective responses. Patients with initial SD were unlikely to have an objective response, but > 1 of 3 patients with MR/PR on first evaluation ultimately had complete response. I/T/DIN/GM-CSF was associated with extended PFS in responders both during and after discontinuation of treatment. This study establishes a new comparator for response and survival in patients with relapsed HRNB.


Subject(s)
Granulocyte-Macrophage Colony-Stimulating Factor , Neuroblastoma , Child , Humans , Adult , Progression-Free Survival , Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use , Irinotecan/therapeutic use , Temozolomide/therapeutic use , Retrospective Studies , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Neuroblastoma/pathology
7.
BMC Med Educ ; 21(1): 331, 2021 Jun 08.
Article in English | MEDLINE | ID: mdl-34103029

ABSTRACT

BACKGROUND: Previous studies have suggested that resident physicians are the most meaningful teachers during the clinical clerkships of third-year medical students (MS3s). Unfortunately, residents often feel unprepared for this crucial role. The pediatrics clerkship at our institution identified a paucity in the frequency of resident-led teaching with MS3s. Lack of confidence, suboptimal teaching space, and insufficient time were cited as the most significant barriers. To enhance resident-led teaching of MS3s, we created teaching scripts of general pediatrics topics accessible via a smartphone application (app). METHODS: Prior to the implementation of the app, MS3s and pediatric residents were surveyed on clerkship teaching practices. From May 2017 through July 2018, pediatric residents working with MS3s were introduced to the app, with both groups queried on resident teaching habits afterward. We compared pre-intervention and post-intervention data of time spent teaching, teaching frequency, and a ranking of pediatric resident teaching performance compared to residents of other MS3 core clerkships. RESULTS: 44 out of 90 residents (49%) responded to a pre-intervention survey on baseline teaching habits. 49 out of 61 residents (80%) completed our post-intervention survey. Pre-intervention, 75% (33/44) of residents reported spending less than 5 min per teaching session on average. Post-intervention, 67% (33/49) reported spending more than 5 min (p < 0.01). 25% (11/44) of residents reported teaching at least once per day pre-intervention, versus 55% (27/49, p = 0.12) post-intervention. Post-intervention data demonstrated a statistically significant correlation between app use and increased frequency of teaching (p < 0.01). The MS3 average ranking of pediatric resident teaching increased from 2.4 to 3.4 out of 6 (p < 0.05) after this intervention. CONCLUSIONS: Residency programs looking to reform resident-led teaching, particularly of residents early in their training, should consider our novel approach. In addition to addressing barriers to teaching and creating a platform for near-peer teaching, it is adaptable to any specialty or learner level. Future direction includes developing objective measures for teaching performance and content proficiency to better assess our intervention as an educational curriculum, as well as further investigation of the intervention as a controlled trial.


Subject(s)
Clinical Clerkship , Internship and Residency , Students, Medical , Child , Curriculum , Humans , Smartphone , Teaching
8.
Transpl Infect Dis ; 22(4): e13283, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32267590

ABSTRACT

BACKGROUND: Adenovirus (AdV) is increasingly recognized as a threat to successful outcomes after allogeneic hematopoietic cell transplantation (allo-HCT). Guidelines have been developed to inform AdV screening and treatment practices, but the extent to which they are followed in clinical practice in the United States is still unknown. The incidence of AdV in the United States is also not well documented. The main objectives of the AdVance US study were thus to characterize current AdV screening and treatment practices in the United States and to estimate the incidence of AdV infection in allo-HCT recipients across multiple pediatric and adult transplant centers. METHODS: Fifteen pediatric centers and 6 adult centers completed a practice patterns survey, and 15 pediatric centers and four adult centers completed an incidence survey. RESULTS: The practice patterns survey results confirm that pediatric transplant centers are more likely than adult centers to routinely screen for AdV, and are also more likely to have a preemptive AdV treatment approach compared to adult centers. Perceived risk of AdV infection is a determining factor for whether routine screening and preemptive treatment are implemented. Most pediatric centers screen higher-risk patients for AdV weekly, in blood, and have a preemptive AdV treatment approach. The incidence survey results show that from 2015 to 2017, a total of 1230 patients underwent an allo-HCT at the 15 pediatric transplant centers, and 1815 patients underwent an allo-HCT at the 4 adult transplant centers. The incidences of AdV infection, AdV viremia, and AdV viremia ≥ 1000 copies/mL within 6 months after the first allo-HCT were 23%, 16%, and 9%, respectively, for patients at pediatric centers, and 5%, 3%, and 2%, respectively, for patients at adult centers. CONCLUSIONS: These findings provide a more recent estimate of the incidence of AdV infection in the United States, as well as a multicenter view of practice patterns around AdV infection screening and intervention criteria, in pediatric and adult allo-HCT recipients.


Subject(s)
Adenoviridae Infections/epidemiology , Hematopoietic Stem Cell Transplantation/adverse effects , Practice Patterns, Physicians'/statistics & numerical data , Transplant Recipients/statistics & numerical data , Adenoviridae Infections/prevention & control , Adolescent , Adult , Antiviral Agents/administration & dosage , Child , Female , Humans , Incidence , Male , Retrospective Studies , Surveys and Questionnaires , Transplantation, Homologous/adverse effects , United States/epidemiology , Viremia/epidemiology
9.
Fetal Pediatr Pathol ; 39(1): 85-89, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31286806

ABSTRACT

Introduction: Endobronchial granular cell tumors are uncommon in the pediatric population. Case report: A 9-year-old female presented with respiratory failure due to an endobronchial tumor. After debulking and diagnosis, she underwent thoracotomy with right upper lobe resection and bronchoplasty. Pathology demonstrated an endobronchial S-100 negative granular cell tumor, which to our knowledge, is the first such report in the literature. Conclusion: Endobronchial granular cell tumors may cause obstructive respiratory failure, are amenable to surgery, and may be S-100 negative.


Subject(s)
Bronchi/pathology , Granular Cell Tumor/pathology , Respiratory Insufficiency/etiology , Respiratory Insufficiency/pathology , Bronchoscopy/methods , Child , Female , Granular Cell Tumor/diagnosis , Humans
10.
Infect Dis Ther ; 8(2): 301-306, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30989592

ABSTRACT

INTRODUCTION: Increased diversity of the intestinal microbiome has been significantly associated with lower mortality after hematopoietic stem cell transplant (HSCT). Probiotics, such as Lactobacillus species with defined probiotic potential, may have beneficial properties including restoration of commensal species to the intestinal tract, anti-microbial effects, and healing of the intestinal mucosa. However, the use of probiotics in immune-compromised patients raises concerns, specifically regarding the risk for possible Lactobacillus bacteremia. Risk of bacteremia is an even greater concern in HSCT patients with breakdown of mucosal barriers, specifically patients with Clostridium difficile infection (CDI) or gastrointestinal graft-versus-host disease (GVHD). Minimal data have been reported on the safety of probiotics in these high-risk HSCT populations. METHODS: We performed a retrospective study of allogeneic HSCT recipients at our institution between 2011 and 2016, and identified 14 patients (median age 7 years) prescribed probiotics, 10 of whom received probiotics prior to day 100 after HSCT. RESULTS: Eight of ten patients were diagnosed with acute GVHD, four of whom (40%) specifically had acute GVHD involving the gastrointestinal tract. Five patients (50%) on probiotics prior to day 100 were diagnosed with CDI (median onset at day 13 post-transplant). There were no cases of Lactobacillus bacteremia, including in patients with GVHD or CDI. CONCLUSION: This small case series supports the safe use of probiotics in a high-risk population of pediatric HSCT patients with compromised intestinal mucosal integrity. Further studies are needed to determine if probiotics have benefit in preventing and treating gastrointestinal GVHD or CDI.

12.
PRiMER ; 2: 17, 2018.
Article in English | MEDLINE | ID: mdl-32818189

ABSTRACT

INTRODUCTION: The US Latino population is projected to double over the next 50 years while the proportion of Latino physicians is expected to decrease over the same interval. Spanish curricula within medical schools are common but rarely assess learners for proficiency and are often not incentivized. Family physicians are well positioned to promote the effective delivery of culturally and linguistically appropriate care to Latino patients with limited English proficiency (LEP). Our aim was to develop a replicable, incentivized, medical Spanish curriculum to promote fluency. METHODS: We developed a peer-taught, interactive, case-based medical Spanish curriculum for fourth-year medical students at a single medical school. All fourth-year medical students were eligible to enroll. Seventeen students completed pre- and postintervention questionnaires to rate their self-efficacy in medical Spanish comprehension and vocabulary. At the end of the course, students were also assessed for oral Spanish language skills by a standardized patient (SP). RESULTS: Students rated themselves as having improved at completing nearly all components of the medical interview and physical in Spanish after completing the course (15/16 tasks, P<0.001). CONCLUSION: This peer-led medical Spanish course shows promise as a feasible and sustainable curriculum for teaching medical Spanish and assessing fluency among fourth-year medical students. Establishing a cohort of peers as teachers addresses concerns about cost and reduces the need for faculty support.

13.
Science ; 337(6093): 485-7, 2012 Jul 27.
Article in English | MEDLINE | ID: mdl-22837528

ABSTRACT

How do we decide if the people we meet and the things we see are familiar or new? If something is new, we need to encode it as a memory distinct from already stored episodes, using a process known as pattern separation. If familiar, it can be used to reactivate a previously stored memory, by a process known as pattern completion. To orchestrate these conflicting processes, current models propose that the episodic memory system uses environmental cues to establish processing biases that favor either pattern separation during encoding or pattern completion during retrieval. To assess this theory, we measured how people's memory formation and decisions are influenced by their recent engagement in episodic encoding and retrieval. We found that the recent encoding of novel objects improved subsequent identification of subtle changes, a task thought to rely on pattern separation. Conversely, recent retrieval of old objects increased the subsequent integration of stored information into new memories, a process thought to rely on pattern completion. These experiments provide behavioral evidence that episodic encoding and retrieval evoke lingering biases that influence subsequent mnemonic processing.


Subject(s)
Hippocampus/physiology , Memory, Episodic , Memory , Mental Recall , Cues , Humans , Learning
SELECTION OF CITATIONS
SEARCH DETAIL
...